Laurus Labs Limited (NSE:LAURUSLABS)
985.70
-15.35 (-1.53%)
Nov 11, 2025, 3:30 PM IST
Laurus Labs Revenue
Laurus Labs had revenue of 16.53B INR in the quarter ending September 30, 2025, with 35.12% growth. This brings the company's revenue in the last twelve months to 63.58B, up 25.83% year-over-year. In the fiscal year ending March 31, 2025, Laurus Labs had annual revenue of 55.54B with 10.18% growth.
Revenue (ttm)
63.58B
Revenue Growth
+25.83%
P/S Ratio
8.37
Revenue / Employee
10.31M
Employees
6,167
Market Cap
532.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 55.54B | 5.13B | 10.18% |
| Mar 31, 2024 | 50.41B | -10.00B | -16.55% |
| Mar 31, 2023 | 60.41B | 11.05B | 22.39% |
| Mar 31, 2022 | 49.36B | 1.22B | 2.54% |
| Mar 31, 2021 | 48.14B | 19.82B | 69.99% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Biocon | 157.71B |
| Mankind Pharma | 135.46B |
| Glenmark Pharmaceuticals | 134.56B |
Laurus Labs News
- 15 days ago - Laurus Labs shares rise over 2% today as US FDA concludes “no quality unit oversight” at Hetero Labs’ Vishakhapatnam warehouse - Business Upturn
- 15 days ago - Top stocks to buy: Stock recommendations for the week starting October 27, 2025 - check list - The Times of India
- 15 days ago - Top stocks to buy today: Stock recommendations for October 27, 2025 - check list - The Times of India
- 18 days ago - DAM Capital bullish on Laurus Labs, cites CDMO traction and lower net debt in strong Q2 - Business Upturn
- 18 days ago - Goldman Sachs cautious on Laurus despite 126% YoY EBITDA growth; valuations seen full - Business Upturn
- 18 days ago - Jefferies cautious on Laurus Labs despite Q2 beat; $600m Vizag capex to extend investment cycle - Business Upturn
- 19 days ago - Laurus Labs reports sharp rise in profit and revenue for second quarter of 2025 - The Times of India
- 19 days ago - Laurus Labs Ltd (BOM:540222) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and ... - GuruFocus